Immune‐mediated epilepsies
Summary A pathogenic role of immunity in epilepsies has long been suggested based on observations of the efficacy of immune‐modulating treatments and, more recently, by the finding of inflammation markers including autoantibodies in individuals with a number of epileptic disorders. Clinical and expe...
Saved in:
Published in | Epilepsia (Copenhagen) Vol. 52; no. s3; pp. 5 - 11 |
---|---|
Main Authors | , , , |
Format | Journal Article Conference Proceeding |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.05.2011
Wiley-Blackwell |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Summary
A pathogenic role of immunity in epilepsies has long been suggested based on observations of the efficacy of immune‐modulating treatments and, more recently, by the finding of inflammation markers including autoantibodies in individuals with a number of epileptic disorders. Clinical and experimental data suggest that both innate and adaptive immunity may be involved in epilepsy. Innate immunity represents an immediate, nonspecific host response against pathogens via activation of resident brain immune cells and inflammatory mediators. These are hypothesized to contribute to seizures and epileptogenesis. Adaptive immunity employs activation of antigen‐specific B and T lymphocytes or antibodies in the context of viral infections and autoimmune disorders. In this article we critically review the evidence for pathogenic roles of adaptive immune responses in several types of epilepsy, and discuss potential mechanisms and therapeutic targets. We highlight future directions for preclinical and clinical research that are required for improved diagnosis and treatment of immune‐mediated epilepsies. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
ISSN: | 0013-9580 1528-1167 1528-1167 |
DOI: | 10.1111/j.1528-1167.2011.03029.x |